Financial Performance Summary - In 2024, the company's total revenue was 984.52 million yuan, representing a year-on-year increase of 2.96% compared to 956.26 million yuan in 2023 [2][3] - The net profit attributable to shareholders was a loss of 105.57 million yuan, a significant decline of 193.80% from a profit of 112.54 million yuan in 2023 [2][3] - The gross profit margin decreased to 47.09%, down by 2.49 percentage points year-on-year, while the net profit margin was -10.82%, a drop of 19.25 percentage points [3] Q1 2025 Performance - In the first quarter of 2025, the company reported revenue of 264.81 million yuan, an increase of 7.56% from 246.21 million yuan in the same period last year [5][6] - The net profit attributable to shareholders was 21.76 million yuan, marking a 100.03% increase from 10.88 million yuan in Q1 2024 [5][6] - The net cash flow from operating activities improved significantly to 8.51 million yuan, compared to a negative cash flow of 19.50 million yuan in the previous year [5][6] Company Overview - The company, Kellytai (stock code: 300326), was established in 2005 and specializes in the research, development, production, sales, and service of orthopedic implant medical devices [8] - Its main business includes minimally invasive intervention systems for vertebroplasty, orthopedic trauma implants, and low-temperature radiofrequency surgical equipment and consumables [8] - The company has expanded into the low-temperature radiofrequency surgical equipment sector through the acquisition of the American company Elliquence, targeting treatments for herniated discs and painful disc tears [8]